[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. 68(6): 394-424.
[2] Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019. 69(5): 363-385.
[3] Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007. 98(12): 1817-24.
[4] Mittal V, El Rayes T, Narula N, McGraw TE, Altorki NK, Barcellos-Hoff MH. The Microenvironment of Lung Cancer and Therapeutic Implications. Adv Exp Med Biol. 2016. 890: 75-110.
[5] Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 2015. 368(1): 7-13.
[6] Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012. 21(3): 309-22.
[7] Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013. 4: 2612.
[8] Shah N, Wang P, Wongvipat J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017. 6.
[9] Priedigkeit N, Watters RJ, Lucas PC, et al. Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight. 2017. 2(17).
[10] Alonso MH, Aussó S, Lopez-Doriga A, et al. Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. Br J Cancer. 2017. 117(3): 421-431.
[11] Jia D, Li S, Li D, Xue H, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging (Albany NY). 2018. 10(4): 592-605.
[12] Yan H, Qu J, Cao W, et al. Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. Cancer Immunol Immunother. 2019. 68(12): 1971-1978.
[13] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011. 144(5): 646-74.
[14] Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009. 54(1): 12-27.
[15] Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995. 75(12): 2844-52.
[16] Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016. 5(3): 288-300.
[17] Gao D, Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med. 2009. 15(8): 333-43.
[18] Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013. 501(7467): 346-54.
[19] Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013. 13(10): 739-52.
[20] Wang J, Yang L, Yu L, et al. Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer. Oncotarget. 2017. 8(10): 17050-17058.
[21] Twum DY, Colligan SH, Hoffend NC, et al. IFN regulatory factor-8 expression in macrophages governs an antimetastatic program. JCI Insight. 2019. 4(3).
[22] Mattei F, Schiavoni G, Sestili P, et al. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia. 2012. 14(12): 1223-35.
[23] Liang J, Lu F, Li B, et al. IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function. Cell Cycle. 2019. 18(23): 3300-3312.
[24] Dyck L, Mills K. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017. 47(5): 765-779.
[25] Antonia SJ, Muñoz-Antonia T, Soldevila G, Miller J, Flavell RA. B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Res. 1995. 55(11): 2253-6.
[26] Jia J, Wang Z, Li X, Wang Z, Wang X. Morphological characteristics and co-stimulatory molecule (CD80, CD86, CD40) expression in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 2012. 160(2): 223-7.
[27] Feng XY, Lu L, Wang KF, et al. Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma. Future Oncol. 2019. 15(5): 473-483.
[28] Puls KL, Hogquist KA, Reilly N, Wright MD. CD53, a thymocyte selection marker whose induction requires a lower affinity TCR-MHC interaction than CD69, but is up-regulated with slower kinetics. Int Immunol. 2002. 14(3): 249-58.
[29] Yunta M, Lazo PA. Apoptosis protection and survival signal by the CD53 tetraspanin antigen. Oncogene. 2003. 22(8): 1219-24.
[30] Todros-Dawda I, Kveberg L, Vaage JT, Inngjerdingen M. The tetraspanin CD53 modulates responses from activating NK cell receptors, promoting LFA-1 activation and dampening NK cell effector functions. PLoS One. 2014. 9(5): e97844.
[31] Krautwald S. IL-16 activates the SAPK signaling pathway in CD4+ macrophages. J Immunol. 1998. 160(12): 5874-9.
[32] Mathy NL, Scheuer W, Lanzendörfer M, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000. 100(1): 63-9.
[33] Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim Biophys Acta. 2016. 1865(2): 255-65.
[34] Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, et al. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surg Oncol. 2017. 26(3): 278-285.
[35] Nagai Y, Shimazu R, Ogata H, et al. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood. 2002. 99(5): 1699-705.
[36] Kikuchi J, Kuroda Y, Koyama D, et al. Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. Cancer Res. 2018. 78(7): 1766-1778.
[37] Gottfried E, Faust S, Fritsche J, et al. Identification of genes expressed in tumor-associated macrophages. Immunobiology. 2003. 207(5): 351-9.
[38] Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015. 16(6): 704-15.
[39] Töpfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015. 194(7): 3201-12.
[40] Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology. 2013. 23(2): 178-87.
[41] Shabo I, Olsson H, Stål O, Svanvik J. Breast cancer expression of DAP12 is associated with skeletal and liver metastases and poor survival. Clin Breast Cancer. 2013. 13(5): 371-7.
[42] Wang Y, Zheng B, Xu M, et al. Prediction and analysis of Hub Genes in Renal Cell Carcinoma based on CFS Gene selection method combined with Adaboost algorithm. Med Chem. 2019 .
[43] Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol. 2015. 16(11): 1114-23.
[44] Consonni M, Dellabona P, Casorati G. Potential advantages of CD1-restricted T cell immunotherapy in cancer. Mol Immunol. 2018. 103: 200-208.
[45] Li Y, Zhao C, Liu J, et al. CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity. Oncol Rep. 2019. 41(5): 2679-2688.